Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab + Nab-paclitaxel in Previously Treated Advanced NSCLC
NCT02730247Phase 2Completed
- Start
- Jul 2017
- Primary completion
- Sep 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in non-small cell lung cancer (NSCLC). Primary endpoints: Progression-free Survival up to 26 months and Worst Grade of Adverse Event Experienced up to 26 months. Started Jul 2017; status: completed.
02
Drugs
ramucirumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02730247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02730247.